Switch theme
Sign up to access all valuation multiples
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Commercial sales segment, Contract Development & Manufacturing Organization segment, and Other segment. The majority of revenue is derived from the Commercial sales segment. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
2007
153
LTM Revenue $620M
LTM EBITDA $163M
$2.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bora Pharmaceuticals has a last 12-month revenue of $620M and a last 12-month EBITDA of $163M.
In the most recent fiscal year, Bora Pharmaceuticals achieved revenue of $581M and an EBITDA of $195M.
Bora Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bora Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $429M | $581M | XXX | XXX | XXX |
| Gross Profit | $88.0M | $211M | XXX | XXX | XXX |
| Gross Margin | 21% | 36% | XXX | XXX | XXX |
| EBITDA | $146M | $195M | XXX | XXX | XXX |
| EBITDA Margin | 34% | 34% | XXX | XXX | XXX |
| Net Profit | $42.0M | $91.5M | XXX | XXX | XXX |
| Net Margin | 10% | 16% | XXX | XXX | XXX |
| Net Debt | $110M | $32.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Bora Pharmaceuticals's stock price is TWD 690 (or $21).
Bora Pharmaceuticals has current market cap of TWD 71.2B (or $2.2B), and EV of TWD 84.3B (or $2.5B).
See Bora Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.5B | $2.2B | XXX | XXX | XXX | XXX | $1.30 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Bora Pharmaceuticals has market cap of $2.2B and EV of $2.5B.
Bora Pharmaceuticals's trades at 4.1x LTM EV/Revenue multiple, and 15.6x LTM EBITDA.
Analysts estimate Bora Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Bora Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.5B | XXX | XXX | XXX |
| EV/Revenue | 4.4x | XXX | XXX | XXX |
| EV/EBITDA | 13.0x | XXX | XXX | XXX |
| P/E | 18.1x | XXX | XXX | XXX |
| P/E/Growth | 1.4x | XXX | XXX | XXX |
| EV/FCF | 286.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBora Pharmaceuticals's NTM/LTM revenue growth is 22%
Bora Pharmaceuticals's revenue per employee for the last fiscal year averaged $3.8M, while opex per employee averaged $0.9M for the same period.
Over next 12 months, Bora Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Bora Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Bora Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 36% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 33% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 55% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $3.8M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 13% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 22% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bora Pharmaceuticals acquired XXX companies to date.
Last acquisition by Bora Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Bora Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Bora Pharmaceuticals founded? | Bora Pharmaceuticals was founded in 2007. |
| Where is Bora Pharmaceuticals headquartered? | Bora Pharmaceuticals is headquartered in Taiwan. |
| How many employees does Bora Pharmaceuticals have? | As of today, Bora Pharmaceuticals has 153 employees. |
| Is Bora Pharmaceuticals publicy listed? | Yes, Bora Pharmaceuticals is a public company listed on TAI. |
| What is the stock symbol of Bora Pharmaceuticals? | Bora Pharmaceuticals trades under 6472 ticker. |
| When did Bora Pharmaceuticals go public? | Bora Pharmaceuticals went public in 2014. |
| Who are competitors of Bora Pharmaceuticals? | Similar companies to Bora Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Bora Pharmaceuticals? | Bora Pharmaceuticals's current market cap is $2.2B |
| What is the current revenue of Bora Pharmaceuticals? | Bora Pharmaceuticals's last 12-month revenue is $620M. |
| What is the current EBITDA of Bora Pharmaceuticals? | Bora Pharmaceuticals's last 12-month EBITDA is $163M. |
| What is the current EV/Revenue multiple of Bora Pharmaceuticals? | Current revenue multiple of Bora Pharmaceuticals is 4.1x. |
| What is the current EV/EBITDA multiple of Bora Pharmaceuticals? | Current EBITDA multiple of Bora Pharmaceuticals is 15.6x. |
| What is the current revenue growth of Bora Pharmaceuticals? | Bora Pharmaceuticals revenue growth between 2023 and 2024 was 36%. |
| Is Bora Pharmaceuticals profitable? | Yes, Bora Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
